HDFC MF and ADIA Lead ₹777 Crore Block Deal in Corona Remedies
A significant shift in the shareholding pattern of pharmaceutical player Corona Remedies Limited took place on June 17, 2026, as major institutional investors moved to acquire substantial stakes. The massive block deal saw marquee names like HDFC Mutual Fund and the Abu Dhabi Investment Authority (ADIA) entering the fray, signaling strong institutional confidence in the company.
Massive Divestment by Sepia Investments and Anchor Partners
The block deal was primarily driven by the exit of two major sellers. Sepia Investments offloaded 43,28,943 shares of Corona Remedies at a price of ₹1,730 per share, amounting to a deal value of approximately ₹748.9 crore. Adding to this volume, Anchor Partners divested 1,61,861 shares at the same price, contributing another ₹28 crore to the transaction. Combined, these two entities offloaded shares worth roughly ₹776.9 crore in the pharmaceutical company.
HDFC Mutual Fund Dominates the Buy Side
The absorption of these shares was led by a diverse group of twelve institutional investors. HDFC Mutual Fund emerged as the most aggressive buyer, acquiring 24,50,000 shares worth approximately ₹423.9 crore. This single transaction accounted for more than half of the total deal value, underscoring HDFC MF's significant conviction in the stock's future prospects.
Other prominent domestic and international players also participated heavily:
- Aditya Birla Sun Life Mutual Fund acquired 4,90,000 shares worth ₹84.8 crore.
- Invesco Mutual Fund picked up 2,89,017 shares, valued at around ₹50 crore.
- Kotak Mahindra Mutual Fund bought 1,61,861 shares, matching the exact quantity sold by Anchor Partners, worth ₹28 crore.
Global Institutional Interest in Corona Remedies
The deal also highlighted significant interest from global fund managers and sovereign wealth funds. Aberdeen Asian Smaller Companies Investment Trust Plc purchased 4,50,868 shares for approximately ₹78 crore, while the Aberdeen Standard Sicav I - Asian Smaller Companies Fund took up 2,74,132 shares worth ₹47.4 crore.
ಇದಲ್ಲದೆ, ಅಬುಧಾಬಿ ಇನ್ವೆಸ್ಟ್ಮೆಂಟ್ ಅಥಾರಿಟಿ (ADIA) ₹6.8 ಕೋಟಿ ಮೌಲ್ಯದ 39,130 ಷೇರುಗಳನ್ನು ಖರೀದಿಸುವ ಮೂಲಕ ಕ್ಯಾಪ್ ಟೇಬಲ್ (cap table) ಪ್ರವೇಶಿಸಿದೆ. ಇತರ ಅಂತರಾಷ್ಟ್ರೀಯ ಭಾಗವಹಿಸುವವರಲ್ಲಿ ₹25.1 ಕೋಟಿ ಹೂಡಿಕೆ ಮಾಡಿದ WhiteOak Capital Mutual Fund ಮತ್ತು ₹25.7 ಕೋಟಿ ಮೌಲ್ಯದ ಷೇರುಗಳನ್ನು ಖರೀದಿಸಿದ India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund ಸೇರಿವೆ. Factory Mutual Insurance Company ನಂತಹ ಸಣ್ಣ ಮಟ್ಟದ ವಿಶೇಷ ಸಂಸ್ಥೆಗಳು ಸಹ ಭಾಗವಹಿಸಿದ್ದು, ₹1.9 ಕೋಟಿ ಮೌಲ್ಯದ 10,670 ಷೇರುಗಳನ್ನು ಖರೀದಿಸಿವೆ.
ಪ್ರಮುಖ ಅಂಶಗಳು
- ಪ್ರಮುಖ ಸಾಂಸ್ಥಿಕ ನಿರ್ಗಮನ: Sepia Investments ಮತ್ತು Anchor Partners ಒಟ್ಟಾಗಿ Corona Remedies ನಲ್ಲಿ ಸುಮಾರು ₹776.9 ಕೋಟಿ ಮೌಲ್ಯದ ಹೂಡಿಕೆಯಿಂದ ಹೊರಬಂದಿವೆ.
- HDFC MF ಖರೀದಿಯಲ್ಲಿ ಮುಂಚೂಣಿಯಲ್ಲಿ: HDFC Mutual Fund ಪ್ರಮುಖ ಖರೀದಿದಾರನಾಗಿದ್ದು, ಒಟ್ಟು ಡೀಲ್ ಮೌಲ್ಯದ 50% ಕ್ಕಿಂತ ಹೆಚ್ಚು ಪಾಲನ್ನು ಪ್ರತಿನಿಧಿಸುವ ₹423.9 ಕೋಟಿ ಮೌಲ್ಯದ ಷೇರುಗಳನ್ನು ಖರೀದಿಸಿದೆ.
- ಹೆಚ್ಚಿನ ಸಾಂಸ್ಥಿಕ ವಿಶ್ವಾಸ: ADIA ಮತ್ತು ವಿವಿಧ Aberdeen ಫಂಡ್ಗಳಂತಹ ಜಾಗತಿಕ ಸಂಸ್ಥೆಗಳ ಭಾಗವಹಿಸುವಿಕೆಯು ಫಾರ್ಮಾ ವಲಯದಲ್ಲಿ ಬಲವಾದ ಅಂತರಾಷ್ಟ್ರೀಯ ಸಾಂಸ್ಥಿಕ ಆಸಕ್ತಿಯನ್ನು ಸೂಚಿಸುತ್ತದೆ.